Crinetics Reports Early PALSONIFY Revenue, Strong Cash, and Advances Multiple Programs to Phase 3
CRNX has more than doubled off its 52-week low of $24.1.
Summary
Crinetics Pharmaceuticals reported preliminary Q4 2025 net product revenue for PALSONIFY exceeding $5 million, alongside a robust cash position of $1.4 billion and the initiation of multiple Phase 3 clinical trials for key pipeline assets.
Key Events · Product Development and Regulatory · CRNX
-
Preliminary Q4 2025 PALSONIFY Revenue
Crinetics expects to report net product revenue from PALSONIFY (paltusotine) of over $5.0 million for the three months ended December 31, 2025, indicating early commercial success for its first marketed product.
-
Strong Financial Position
The company reported approximately $1.4 billion in cash, cash equivalents, and investments as of January 8, 2026, providing a substantial operational runway for its development programs.
-
Multiple Phase 3 Trials Initiated
Crinetics initiated Phase 3 studies for paltusotine in carcinoid syndrome and atumelnant in adult congenital adrenal hyperplasia, advancing key pipeline assets into late-stage development.
-
Pipeline Expansion
A Phase 1/2 study for CRN09682 in neuroendocrine tumors was also initiated, further diversifying the company's clinical pipeline.
Analysis · CRNX · Life Sciences
This 8-K, coupled with the J.P. Morgan Healthcare Conference presentation, provides a comprehensive positive update for Crinetics. The preliminary net product revenue for PALSONIFY demonstrates early commercial traction for its first marketed product, a critical milestone for a life sciences company. The substantial cash, cash equivalents, and investments of approximately $1.4 billion provide a strong financial runway, significantly de-risking future operations. Furthermore, the initiation of multiple Phase 3 studies for paltusotine in carcinoid syndrome and atumelnant in adult congenital adrenal hyperplasia, along with a Phase 1/2 for CRN09682 in neuroendocrine tumors, highlights significant progress across its pipeline. These advancements position Crinetics for continued growth and potential market leadership in endocrinology.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.5% of the 1531 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRNX was trading at $54.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $24.10 to $57.99. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.